CatalYm
Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems.
About CatalYm
CatalYm has discovered that GDF-15 is a key factor in helping cancer resist treatment. They are developing it as a safe and effective immune therapy for solid tumors. GDF-15, which normally helps the body tolerate pregnancy, is used by cancer cells to avoid being attacked by the immune system.
Legal Name
: CatalYm
Headquarters
: Munich, Germany
Business Model
:
Founding Date
: 1970
No. of Employees
:
Founding Members
Recently Added Startups
UXPin
UXPin’s design editor lets you create the perfect user experience from start to finish without leaving the app
Related Post
CatalYm funding news – Munich-based CatalYm Secures $150 Million in Series D Round Funding
Top 12 HealthTech Startups in Germany
Startups Hit €125 million+ in 2024 Funding Report
Biotech
Astraveus
They build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies.
Novartis
Rethink medicine to help people live longer and healthier lives, giving patients, doctors, and communities the tools they need to face serious illnesses with confidence.
